Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A